全文获取类型
收费全文 | 26236篇 |
免费 | 2724篇 |
国内免费 | 1117篇 |
专业分类
耳鼻咽喉 | 147篇 |
儿科学 | 953篇 |
妇产科学 | 363篇 |
基础医学 | 3184篇 |
口腔科学 | 434篇 |
临床医学 | 2118篇 |
内科学 | 7649篇 |
皮肤病学 | 206篇 |
神经病学 | 505篇 |
特种医学 | 797篇 |
外国民族医学 | 3篇 |
外科学 | 2804篇 |
综合类 | 3820篇 |
现状与发展 | 6篇 |
预防医学 | 1145篇 |
眼科学 | 168篇 |
药学 | 2357篇 |
11篇 | |
中国医学 | 1746篇 |
肿瘤学 | 1661篇 |
出版年
2024年 | 79篇 |
2023年 | 504篇 |
2022年 | 693篇 |
2021年 | 1140篇 |
2020年 | 1184篇 |
2019年 | 1106篇 |
2018年 | 1114篇 |
2017年 | 1194篇 |
2016年 | 1110篇 |
2015年 | 1149篇 |
2014年 | 1763篇 |
2013年 | 1991篇 |
2012年 | 1536篇 |
2011年 | 1717篇 |
2010年 | 1412篇 |
2009年 | 1378篇 |
2008年 | 1424篇 |
2007年 | 1407篇 |
2006年 | 1227篇 |
2005年 | 1035篇 |
2004年 | 821篇 |
2003年 | 668篇 |
2002年 | 588篇 |
2001年 | 515篇 |
2000年 | 382篇 |
1999年 | 354篇 |
1998年 | 323篇 |
1997年 | 243篇 |
1996年 | 252篇 |
1995年 | 202篇 |
1994年 | 212篇 |
1993年 | 147篇 |
1992年 | 135篇 |
1991年 | 112篇 |
1990年 | 115篇 |
1989年 | 84篇 |
1988年 | 81篇 |
1987年 | 96篇 |
1986年 | 77篇 |
1985年 | 94篇 |
1984年 | 80篇 |
1983年 | 49篇 |
1982年 | 73篇 |
1981年 | 55篇 |
1980年 | 37篇 |
1979年 | 29篇 |
1978年 | 28篇 |
1977年 | 19篇 |
1976年 | 15篇 |
1974年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
31.
32.
Aim:To investigate the clinical characteristics of patients with Peyronie's disease(PD)and diabetes mellitus(DM).Methods:During an 8-year period,a total of 307 men seen at our outpatient clinic were diagnosed with PD.Clinicalcharacteristics,penile deformities and the erectile status of patients with PD and DM together(n=102)were retro-spectively analyzed and compared to patients with PD alone with no risk factors for systemic vascular diseases(n=97).Results:The prevalence of PD among men with DM and sexual dysfunction was 10.7%.The mean ageof diabetic patients with PD was(55.9±8.9)years;in the no risk factor group it was(48.5±9.0)years(P<0.05).The median duration of DM was 5 years.The majority of diabetic patients with PD(56.0%)presented in the chronicphase(P<0.05),and they were more likely to have a severe penile deformity(>60°)than the no risk factor group(P<0.05).In the diabetic group,the most common presenting symptom was penile curvature(81.4 %),followedby a palpable nodule on the shaft of the penis(22.5%)and penile pain with erection(14.7 %).A total of 19.6 % ofpatients were not aware of their penile deformities in the diabetic group.Erectile function,provided by history and inresponse to intracavernosal injection and a stimulation test,was significantly diminished in patients with PD and DM(P<0.05).Conclusion:DM probably exaggerates the fibrotic process in PD.Diabetic patients with PD have ahigher risk of severe deformity and erectile dysfunction(ED).PD seems to be a silent consequence of DM andshould be actively sought in diabetic men.(Asian J Androl 2006 Jan;8:75-79) 相似文献
33.
34.
35.
36.
Renal fibrosis and the origin of the renal fibroblast. 总被引:4,自引:0,他引:4
Many studies have determined that the extent of tubulointerstitialinvolvement, particularly fibrosis, correlates better with renalfunction than glomerular changes do, thus, the extent of tubulointerstitialdamage in any given renal biopsy has important implicationsfor the renal prognosis of the patient (summarized in [1]).Tubulointerstitial fibrosis is characterized by the accumulationof extracellular matrix components including collagen typesI, III, IV, proteoglycans and fibronectin. In recent years,much controversy has been created in the nephrology communityregarding the origin of matrix-producing cells in the kidney.Several possibilities exist, including activation of residentinterstitial fibroblasts, migrating haematopoietic or mesenchymalstem cells from the bone marrow, periadventitial cells and epithelialmesenchymaltransition (EMT) of tubular epithelial cells. This review summarizesrecent data indicating the possible origin of matrix-producingcells in the kidney, and illustrates from a clinical point of 相似文献
37.
目的:探讨骨调素(OPN)和单核细胞趋化蛋白(MCP-1)在大鼠梗阻性模型中的表达及其在肾脏纤维化发病机制中的作用.方法:采用-单侧输尿管结扎制造梗阻性肾病模型,分别于造模后7 d、14 d取肾组织,应用HE染色观察肾脏病理改变,免疫组化方法检测肾组织畔OPN和MCP-1蛋白的表达,应用逆转录-聚合酶链式反应(RT-PCR)法观察肾组织中OPN mRNA和MCP-1 mRNA的变化.结果:OPN、MCP-1表达主要位于肾小管上皮细胞,随着梗阻时间的延长,肾组织中OPN、MCP-1蛋白和mRNA表达明显增加.结论:OPN、MCP-1蛋白和mRNA在梗阻性肾病大鼠肾组织表达明显增加介导炎症过程,参与肾间质纤维化. 相似文献
38.
C. M. Gordon E. Binello M. S. LeBoff M. E. Wohl C. J. Rosen A. A. Colin 《Osteoporosis international》2006,17(5):783-790
Introduction Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss
are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients
between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA)
and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1β, tumor necrosis factor α,
and interleukin-6.
Methods We studied 32 outpatients (18 females; mean age: 26.2 ± 7.9 years) at a tertiary care medical center. The subjects had venous
samples obtained, underwent anthropometric and bone mineral density (BMD) measurements, and completed a health survey. Serum
IGF-I concentrations were below the age-adjusted mean in 78% of the participants, and DHEA sulfate (DHEAS) concentrations
were low in 72%. Serum concentrations of all cytokines were on the low side of normal; nonetheless, there was a modest inverse
correlation between IL-1β and BMD at all sites.
Results In univariate analyses, IGF-I and DHEAS were significant correlates of BMD or bone mineral content. In final multivariate
models controlling for anthropometric and other variables of relevance to bone density, only IGF-I was identified as a significant
independent skeletal predictor. While alterations in DHEAS, IGF-I, and specific cytokines may contribute to skeletal deficits
in patients with CF, of these factors a low IGF-I concentration appears to be most strongly correlated with BMD.
Conclusions These findings may have therapeutic implications for enhancing bone density in these patients. 相似文献
39.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
40.
PGA指数和透明质酸在诊断慢性乙肝肝纤维化中的价值 总被引:1,自引:0,他引:1
目的:寻找一种简便实用的诊断慢性乙型肝炎纤维化的方法。方法:以78例经肝穿刺病理证实的慢性乙型肝炎为对象,测定并比较了由PT、GGT、ApoA1组成的PGA指数和HA、LN、PⅢP、C-IV与肝内纤维化程度(S)和炎症活动度(G)的关系。结果:(1)LN、PⅢP、C-IV在轻度慢性乙肝时无明显升高,在中度慢性乙肝时明显高于正常,但与轻度慢性乙肝无差异,而PGA指数和HA不仅在轻度慢性乙肝时显著升高,而且在轻中度间差异明显.因重度慢性乙肝和活动性肝硬化时,五项指标均显著增高。(2)在G2-4期,HA、LN、PⅢP、C-IV均明显高升,但在G1期,只有PGA指数高于正常,且各期间差异显著。(3)在S1-2期,只有PGA指数、HA、C-IV明显上升,但C-IV的上升幅度远低于PGA指数和HA。(4)加以PGA>4.5或HA>200μg/L作为判断临界值,则两者判断肝纤维化的敏感性均>94%,精确性>91%,特异性>86%,如两者结合,则分别达到98.3%、95.2%和96.4%。结论:PGA指数和HA均是反映慢性乙型肝炎患者肝内纤维化程度的良好指标,两者联合检测则可达到最大的价值效益比。 相似文献